Disc Medicine, Inc. $IRON Shares Acquired by Eventide Asset Management LLC

Eventide Asset Management LLC lifted its holdings in shares of Disc Medicine, Inc. (NASDAQ:IRON) by 28.4% during the 4th quarter, Holdings Channel.com reports. The firm owned 395,392 shares of the company’s stock after acquiring an additional 87,349 shares during the period. Eventide Asset Management LLC’s holdings in Disc Medicine were worth $31,398,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in IRON. JPMorgan Chase & Co. boosted its holdings in shares of Disc Medicine by 110.0% during the fourth quarter. JPMorgan Chase & Co. now owns 1,581,127 shares of the company’s stock worth $125,557,000 after purchasing an additional 828,248 shares during the last quarter. Jennison Associates LLC acquired a new stake in shares of Disc Medicine during the fourth quarter worth $42,252,000. Pictet Asset Management Holding SA boosted its holdings in shares of Disc Medicine by 10,968.6% during the fourth quarter. Pictet Asset Management Holding SA now owns 394,374 shares of the company’s stock worth $31,317,000 after purchasing an additional 390,811 shares during the last quarter. Vestal Point Capital LP boosted its holdings in shares of Disc Medicine by 257.1% during the third quarter. Vestal Point Capital LP now owns 500,000 shares of the company’s stock worth $33,040,000 after purchasing an additional 360,000 shares during the last quarter. Finally, Assenagon Asset Management S.A. boosted its holdings in shares of Disc Medicine by 3,329.8% during the fourth quarter. Assenagon Asset Management S.A. now owns 357,836 shares of the company’s stock worth $28,416,000 after purchasing an additional 347,403 shares during the last quarter. Institutional investors and hedge funds own 83.70% of the company’s stock.

Disc Medicine Price Performance

Shares of Disc Medicine stock opened at $67.99 on Friday. Disc Medicine, Inc. has a twelve month low of $40.00 and a twelve month high of $99.50. The stock has a market capitalization of $2.59 billion, a P/E ratio of -10.27 and a beta of 0.93. The company has a current ratio of 24.00, a quick ratio of 24.00 and a debt-to-equity ratio of 0.04. The business’s fifty day moving average price is $68.16 and its 200 day moving average price is $72.57.

Disc Medicine (NASDAQ:IRON) last issued its earnings results on Tuesday, May 5th. The company reported ($1.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.62) by ($0.03). As a group, research analysts anticipate that Disc Medicine, Inc. will post -6.74 earnings per share for the current year.

Insider Activity

In other Disc Medicine news, CFO Jean M. Franchi sold 6,257 shares of the firm’s stock in a transaction dated Tuesday, April 14th. The stock was sold at an average price of $69.24, for a total value of $433,234.68. Following the transaction, the chief financial officer directly owned 64,333 shares of the company’s stock, valued at $4,454,416.92. This trade represents a 8.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider William Jacob Savage sold 5,731 shares of the firm’s stock in a transaction dated Monday, April 13th. The shares were sold at an average price of $66.38, for a total value of $380,423.78. Following the completion of the transaction, the insider directly owned 79,480 shares in the company, valued at $5,275,882.40. This trade represents a 6.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 12,388 shares of company stock worth $841,258 over the last three months. 3.76% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on IRON shares. Cantor Fitzgerald decreased their price objective on Disc Medicine from $153.00 to $125.00 and set an “overweight” rating on the stock in a report on Tuesday, February 17th. Wells Fargo & Company lifted their target price on Disc Medicine from $78.00 to $79.00 and gave the company an “overweight” rating in a report on Monday, March 2nd. BMO Capital Markets reduced their target price on Disc Medicine from $120.00 to $100.00 and set an “outperform” rating on the stock in a report on Tuesday, February 17th. Wedbush reiterated an “outperform” rating and issued a $88.00 target price on shares of Disc Medicine in a report on Wednesday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Disc Medicine in a report on Monday, April 20th. Ten equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $105.30.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.